Carbon ion radiotherapy (CIRT) is developing toward a versatile tool in radiotherapy; however, the increased relative biological effectiveness (RBE) of carbon ions in tumors and normal tissues with respect to photon irradiation has to be considered by mathematical models in treatment planning. As a consequence, dose prescription and definition of dose constraints are performed in terms of RBE weighted rather than absorbed dose. The RBE is a complex quantity, which depends on physical variables, such as dose and beam quality as well as on normal tissue-or tumor-specific factors. At present, three RBE models are employed in CIRT: (a) the mixed-beam model, (b) the Microdosimetric Kinetic Model (MKM), and (c) the local effect model. While the LEM is used in Europe, the other two models are employed in Japan, and unfortunately, the concepts of how the nominal RBE-weighted dose is determined and prescribed differ significantly between the European and Japanese centers complicating the comparison, transfer, and reproduction of clinical results. This has severe impact on the way treatments should be prescribed, recorded, and reported. This contribution reviews the concept of the clinical application of the different RBE models and the ongoing clinical CIRT trials in Japan and Europe. Limitations of the RBE models and the resulting radiobiological issues in clinical CIRT trials are discussed in the context of current clinical evidence and future challenges.
INTRODUCTION
Carbon ion radiotherapy (CIRT) presents a new promising treatment option for tumors, which are resistant against conventional radiotherapy with photons. Based on early experience with other ion types, 1 carbon ion therapy was introduced in 1994 in Japan 2 and was continuously developed into a mature radiation therapy modality. [3] [4] [5] [6] [7] By the end of 2015, around 20,000 patients have been treated with CIRT at nine different facilities worldwide.* Besides a more conformal irradiation, CIRT exhibits an increased effectiveness relative to photons, which is aimed to be focused to the tumor while sparing the surrounding normal tissue. 8 The limited knowledge of this increased effectiveness and its prediction by mathematical models, however, pose a major challenge for application of CIRT to new tumor indications and its evaluation within clinical trials.
As in other medical disciplines, reproducibility of the results of modern radiotherapy techniques is considered of paramount importance. This reproducibility of results hinges on two fundamental pivots: comparability of (a) the groups of treated patients and (b) the delivered treatments.
The first aspect is difficult to tackle and the only tool which is unanimously considered as methodologically sound is the prospective randomized clinical trial (RCT) in which randomization assures a fair distribution of known and unknown confounding variables between groups. Nevertheless RCTs are very demanding in terms of economic and human resources and are not devoid of risks for the enrolled patient. Staging systems are widely used to minimize impact of bias and confounding, which pose a problem in nonrandomized series, and to select which therapies should eventually be tested in RCTs. Even these well-established procedures are still an issue in heavy-ion radiotherapy. In fact, many patients treated with CIRT with radical intent had no other curative option as those patients were at the end of scale of the staging systems. Examples are inoperable locally advanced T4 salivary gland cancers or mucosal melanoma, inoperable pelvic spinal and head and neck sarcomas, or inoperable pancreatic cancers. All these patients are considered to have a very poor prognosis; however, a subset of them may still achieve long-term local control with radical CIRT. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] It is easily understood that an adenoid cystic carcinoma (ACC) staged as T4 for cavernous sinus infiltration can be easily treated, whereas the same tumor with the same staging that displaces and compresses the brainstem is almost impossible to control with radical CIRT; but a formally recognized substaging system is lacking and makes comparison of results reported by different centers even more problematic. However, these aspects are not specific for CIRT and will not be dealt here in depth.
Also, the ability to deliver comparable treatments displays peculiar features that are specific to CIRT and they have to be considered carefully. In the broader multidisciplinary setting of cancer therapy, it is widely accepted that pharmacological therapies are easy to standardize, whereas surgical procedures are intrinsically more patient-and surgeon-dependent; however, the general principles of oncological surgery are well-established and complex procedures such as total mesorectal excision or lung lobectomy or enbloc resection of a sacral sarcoma are understood worldwide simply by their name. Radiotherapy (RT) traditionally has always been considered more similar to surgery with respect to its intrinsic variability. There are basically two main aspects that characterize a radiotherapy treatment: irradiated volumes and dose distributions. Target volumes for radiotherapy are defined based on consensus, guidelines, and atlases; however, target volumes for classic CIRT indications are still discussed controversially. For example, ACCs are treated with elective irradiation of bilateral neck nodes (ENI) for all patients in Germany, but ENI is not performed to any patient treated with CIRT in Japan. Lymph node volumes for exclusive CIRT in pancreas cancer employed in Japan are based on the staging system of the Japanese Pancreas Society, and they differ, albeit only moderately, from those recommended by the Radiation Oncology Therapy Group (RTOG). The difficulty in standardizing volumes in these settings should not be minimized; but once again, these difficulties are not specific to CIRT. Dose distributions have traditionally been described by a very limited set of parameters such as total absorbed dose in Gy, number of fractions, absorbed dose per fraction, and overall treatment time. With the availability of more complex and versatile treatment technologies, this synthetic description is considered to be no longer representative for what was actually delivered to the patient, and precise recommendation for standardized reporting have been released by the ICRU. 21, 22 Even RT techniques that do not follow the ICRU recommendation for recording and reporting the treatment (such as gamma knife, cyberknife, and stereotactic ablative radiotherapy) have a limited and well understood set of treatment parameters.
With respect to dose prescription, CIRT introduces an unprecedented degree of complexity as its effect is not determined only by the delivered absorbed dose but instead depends critically on the variable characteristic of spatial dose deposition at the microscopic scale. With the same absorbed dose, the biological effect can vary by a factor of 2-5 according to the ionization density of the particles in the tissue. 23 Although the ionization density is the underlying physical quantity, which determines the biological effect, more specific quantities such as linear energy transfer (LET) or lineal energy (y) are typically used. The spectra of these quantities may differ from voxel to voxel and can be calculated with advanced physical beam models. As the biological effectiveness depends on these spectra, it is impossible for the radiooncologist to directly estimate the tissue response. Thus, although prescribing, recording, and reporting absorbed dose is the obvious choice for all kind of photon-based RT and a fixed scaling factor of 1.1 is employed in proton therapy, substantial differences exist in how CIRT is prescribed, recorded, and reported in different facilities. Although under development, no ICRU report on CIRT is presently available, and in clinical practice, different strategies are employed by different facilities. As one example, the Institute of Modern Physics (IMP) in Lanzhou (China) was treating patients in the early clinical phase by optimizing, delivering, and reporting a uniform absorbed dose of carbon ions scaled by a constant factor of 2.5-3 to account for the increased biological effectiveness. 24 With this approach, the spatial variation of the increase in effectiveness of high-LET radiation was disregarded. The limits of this strategy were fully acknowledged also by colleagues at IMP. 24 All other facilities use the concept of a spatially variable RBE which is calculated according to different radiobiological models and which varies voxel by voxel so that the absorbed dose decreases for increasing RBE. With this approach, the RBE weighted rather than the absorbed dose is optimized, prescribed, recorded, and reported. More recently, also IMP has implemented a model to modulate the absorbed dose according to the variation of the RBE. 25 It is evident that the same RBE weighted dose may result in two rather different treatments, if different RBE models are used. To understand the limits of retrospective comparison of CIRT results at different institution, to reproduce established clinical results in new facilities, and finally to rationally plan multicentric cooperative clinical trials, it is therefore mandatory to understand the general principles behind the different RBE models and the way they are applied clinically.
This contribution reviews the concept of the clinical application of the different RBE models as well as the ongoing clinical CIRT trials in Japan and Europe. Limitations of the RBE models and the resulting radiobiological issues in clinical CIRT trials are discussed in the context of current clinical evidence and future challenges.
REVIEW OF RADIOBIOLOGICAL ISSUES AND CLINICAL TRIALS

2.A. The RBE concept
It is well known that heavy-ion irradiations are more effective than the same absorbed dose of photons and the increased effectiveness is described by the relative biological effectiveness (RBE) defined as follows:
where D photon and D ion are isoeffective absorbed photon and ion doses, respectively. The concept of the RBE allows reducing the response to heavy-ion irradiation to that of photons, where much more clinical experience is available. To distinguish the absorbed ion dose given in units of Gy from the isoeffective photon dose, the latter is termed as RBE-weighted dose and the respective values are expressed in Gy (RBE). 26 The RBE is a complex quantity, which depends on the ion type, LET, the fractional dose as well as on biological characteristics of the irradiated system. Experimentally, it has been shown that the RBE of carbon ions increases with LET up to about 200 keV/lm and that it decreases beyond. 27 Besides the LET dependence, the RBE increases with decreasing fractional dose and the degree of the LET and dose dependence strongly depends on the repair capacity of the biological system after photon irradiation, which is characterized by the value of the a=b parameter in the frame work of the linear-quadratic (LQ) model. 27, 28 The lower the a=b value of the tissue is, the higher will be the RBE of a carbon ion irradiation. In comparison, the impact of the absolute radiosensitivity, given by the parameter a for photon irradiations, is much smaller for fixed a=b values as shown by modeling studies. 29 Additional dependencies of the RBE may arise from other biological factors which impact the radiation tolerance differently for photons and heavy ions. With this respect, environmental factors such as hypoxia in tumors are considered to be most important as suggested by in vitro data. 30, 31 It is assumed that the oxygen enhancement ratio (OER) of hypoxic tumors decreases when moving from low-to high-LET irradiations. As a consequence, it is believed that the RBE of high-LET radiation is higher in hypoxic than in oxic tumors. For a clinical benefit of CIRT over protons, it is generally required that the RBE in the tumor is higher than in the surrounding normal tissue.
Due to the complex dependencies of the RBE, the exact value depends on the specific details of the irradiation (e.g., beam configuration, LET, dose, and the biological system). In experimental in vitro or in vivo studies, the corresponding RBE is termed as experimental RBE. The experimental RBE is a well-defined quantity; however, its value is strictly valid only for the underlying experimental conditions and a direct transfer to patients is generally not possible.
For clinical application of CIRT, the complex dependencies of the RBE have to be considered quantitatively in treatment planning by using radiobiological models. These RBE models describe the dependence of the RBE on the most important physical (e.g., LET and dose) and biological (radiosensitivity) parameters and are used to interpolate the RBE to the specific irradiation conditions of patients.
These RBE models, however, can only be validated for specific experimental conditions [32] [33] [34] ; and although this is important, the transfer of these models to patients additionally requires a clinical dose prescription concept (c.f. Section 2.B). In this context, the clinical RBE was introduced as the ratio of the prescribed absorbed doses of a photon and a carbon ion irradiation, which result in clinically equivalent results. 35 In contrast to the experimental RBE, the clinical RBE is an operational concept, which involves a medical decision. The clinical RBE was originally introduced in neutron radiotherapy, where the spatial variation of the RBE within the treatment field is only small. In CIRT, however, the RBE varies substantially within the SOBP, and therefore, a uniform clinical RBE cannot be determined for all possible treatment fields and dose levels. As this spatial variation of the effectiveness is described by RBE models, the actual clinical RBE may also depend on the selected model, and especially in the LEM, the clinical RBE of individual treatment fields is implicitly defined by the selection of the underlying model parameters.
2.B. RBE models
Several phenomenological and mechanistic RBE models have been developed [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] ; however, only three of them have been applied clinically in CIRT up to now: (a) For passive beam delivery at the Japanese CIRT centers, the phenomenological mixed-beam model was clinically introduced and is still used in some centers. 37, 38 (b) More recently, beam scanning was also introduced at the Japanese Centers, and for this, the Microdosimetric Kinetic Model (MKM) was introduced clinically. [40] [41] [42] (c) For application of the raster scan technique in the European CIRT centers, 23, 50, 51 the local effect model (LEM) 43 is used. Although the initial model (LEM I) was further developed, [44] [45] [46] these versions (LEM II-IV) are not yet clinically applied.
For the technical details of these models, the reader is referred to the cited literature. In this review, we describe the concepts, how these models were introduced for application in patients. As the models were primarily developed based on in vitro data neglecting systemic properties of tissues, this introduction is a critical step. To reduce the uncertainty in this transition, each model includes a step, in which in vitro are replaced by in vivo parameters. This, together with a clinical dose finding process, assures that the main functional dependencies of the RBE are reflected and that the prescribed doses are clinically safe as well as effective. In the following, we summarize the different approaches that are followed by the different RBE models.
2.B.1. Mixed-beam model
In the mixed-beam model, RBE depth-dose profiles were calculated with a conventional LQ-model for a set of clinically applied and passively generated spread-out Bragg peaks (SOBP) using HSG (Human Salivary Gland) cells as biological reference system and 10% cell survival as biological endpoint. 37, 38 As carbon ion irradiations with a dose-averaged LET of 80 keV/lm were found to be biologically equivalent to previously applied neutron beams, the RBE profile was normalized to the clinical neutron RBE at this LET value. In previous studies, the neutron RBE was found to be 3.0 for 16 fractions of 0.9 Gy. By this, only the relative RBE profile is based on in vitro data, while the absolute RBE values are connected to clinical experience in neutron therapy. It has to be noted that in contrast to the approach with LEM, HSG cells exhibit a small shoulder and were, therefore, considered as representative for early responding normal or tumor tissues. Also the neutron RBE refers to early skin and tumor reactions rather than late effects. [52] [53] [54] [55] The absorbed dose profile in the mixed-beam model has been recently recalculated using mouse skin reddening as an endpoint and an almost identical profile has been found. 56, 57 As a further difference, the RBE depth profiles have not been adjusted when the dose per fraction was escalated. This is due to the realization of the SOBP by hardware components in the beam line and this approach is considered as an approximation.
2.B.2. Microdosimetric kinetic model (MKM)
The MKM is derived from microdosimetric biological models and is based on the theory of dual radiation action (TDRA). 58 The MKM estimates the production of lethal lesions in a micrometer-scale region of interest, a so-called domain, as a linear-quadratic function of the specific energy z absorbed by the domain. The MKM was originally developed by Hawkins 39 and was recently modified to correct for saturation in the production of the lethal lesions in case of densely ionizing radiation. 40 Since z ¼ l m y is a direct expression of the amount of energy deposited to a domain of mass m and average chord length l of the cell nucleus size, which is not the case for the LET, the MKM can predict the RBE of various ion species solely as a function of z. Due to this advantage, the original mixed-beam model, which was used for the passive beam delivery in CIRT since 1994, was replaced by the modified MKM for CIRT at NIRS in 2011. 41 In the same way as in the original approach, HSG cells have been selected as a biological reference system in the modified MKM. The RBE-weighted dose distribution of the HSG cells predicted by the MKM is now expressed relative to the "reference carbon ion beam" as explained below and is then scaled to match the clinical experience with CIRT at NIRS based on the mixed-beam model. 42 Although specification of RBE-weighted dose with the new MKM-based dose prescription system does not refer to a photon dose, the RBE profile still reflects the biological effectiveness of the beam exactly relative to the center of the reference SOBP. This system is also considered as a pragmatic approach to be consistent with previous dose prescription with the mixed-beam model, which allows achieving the same clinical effects with the same prescribed dose. This is especially important as dose-fractionation protocols at NIRS aim to exploit the efficacy of hypofractionated treatments, which are distinctly different from that in conventional photon radiotherapy.
With this MKM-based dose prescription system, as mentioned, the reference radiation has been changed from 200 kV x ray in the original model to that at the center of a carbon ion "reference SOBP." This reference SOBP was selected to be a 60-mm SOBP with an initial energy of 350 MeV/u, which is one of the most frequently used therapeutic beams in recent days. The radiation quality, z, throughout the beam is estimated using the GEANT4 Monte Carlo simulation code and the RBE-weighted dose distribution was designed with the modified MKM to achieve the same HSG-cell survival level throughout the target region of the reference beam. In this framework, the absorbed dose at any point within the target region leads to the same HSG-cell survival fraction, if the same RBE-weighted dose is given by the reference beam quality.
Since the RBE in the original mixed-beam model was independent of the dose level, the clinically prescribed doses are directly connected to the absorbed doses, irrespective of the dose level. This connection is realized by the scaling factor, F NIRS , between the prescribed and absorbed doses at the reference point in the original model, which was 2.41 and which scales the biological to clinical dose distribution. The schematic relationship of this approach is shown in Fig. 1 . This formalism is also applied for other, nonreference SOBPs: The prescribed clinical dose is translated to the corresponding in vitro HSG survival level of the reference SOBP using the scaling factor F NIRS , and the absorbed dose of the nonreference SOBP is then determined to achieve the same survival level.
It has to be noted that in the original mixed-beam model, the dose dependence of the RBE is implicitly included in the clinically prescribed doses but does not consider the dose dependence of the shape of the RBE. The clinical dose distribution applied with the MKM, however, additionally considers the dose dependence in the shape of the RBE-depth profile and thus allows for more accurate prediction of the RBE within the SOBP at different dose levels. The difference of physical and clinical dose distributions by the two approaches was examined on various therapeutic conditions, and it was concluded that mean physical doses delivered to target region by the new system agreed to those of the original system within AE 1.5% for prescribed dose levels of 3.6-8.0 Gy (RBE), beam energies of 290-400 MeV/n, and SOBP widths of 30-120 mm. All the facilities in Japan use either the original mixed-beam model or its successor the modified MKM in CIRT.
2.B.3. Local effect model (LEM)
The basic assumption of the clinically applied LEM is that equal local energy depositions lead to equal local biological effects, no matter by which radiation type the energy was transferred. Using the microscopic dose distribution, the survival probability of cells after carbon ion irradiations is calculated based on the cell survival curve for photons. 43, 59 Using the absorbed doses of photon and carbon ion irradiations at the same survival level, the RBE is calculated. Besides the particle spectrum and the detailed track structure of the ions, the LEM requires the size of the cell nucleus and the cell survival curve of photons as biological input parameters, where the latter is parameterized by the radiosensitivity parameters a and b and by the transition dose D t . In cell culture, a and b can be measured, and it has been shown that the RBE of cells is described with reasonable accuracy. 27 The transition from in vitro data to clinical application is achieved by replacing the cellular a=b value of the photon response by clinical a=b values, which result from comparison of different isoeffective fractionation schedules for photons. Regarding the selection of a, it is considered that the RBE is much less dependent on this parameter for fixed value of a=b, and a is therefore selected in the range of typical in vitro values. 29 It then was a clinical decision to start with skull base tumors [60] [61] [62] and to select a=b = 2 Gy being in the lower range of values for late effects in the central nervous tissue. As the RBE increases for decreasing a=b, this selection was considered to be conservative with respect to the risk of side effects. This approach thus focuses on the accurate prediction of the biological effect for late reacting normal tissues.
2.C. Clinical trials
While all ion types offer highly conformal irradiation of the tumor with excellent sparing of the surrounding normal tissue, the clinical rationale of CIRT especially includes the assumption that the RBE within the tumor is higher than in the surrounding normal tissue. Although the respective RBE distribution may be calculated by RBE models, it has to be emphasized that RBE models consider only the dependencies of some of the physical and biological parameters and even these predictions are associated with significant uncertainties. 27, [32] [33] [34] 45 There are many biological factors, which may influence the RBE, but which are not included in the RBE models. For example, it has been shown that differences in the progression status of different tumor sublines as well as the biological heterogeneity within the same subline have less impact on the radiation response for high-LET radiation as compared with photons. As a result, the least-differentiated tumor subline showed the highest RBE. 63 Clinically, this may especially be of advantage for the treatment of undifferentiated tumors with increased radioresistance in photon radiotherapy.
In spite of the involved uncertainty, RBE predictions are helpful to design safe and effective treatments with carbon ion beams. Superiority of CIRT over proton therapy, however, can only be proven in clinical trials. As the dose to normal and tumor tissue as specified by the TPS includes the RBE uncertainty, clinical parameters such as the balance of local tumor control and normal tissue complication probability rather than the underlying RBE-weighted doses have to be compared. Many clinical trials are ongoing in all CIRT center to evaluate this clinically most important question.
2.C.1. Japan
In Japan, the Heavy Ion Medical Accelerator in Chiba (HIMAC) was established at the National Institute of Radiological Sciences (NIRS) as the world's first clinically dedicated CIRT facility in 1994. 64 In 2001, the Hyogo Ion Beam Medical Center (HIBMC) was established, 65 which provides protons and since 2002 carbon ions in the same facility. The third facility in Japan, the Gunma Heavy-Ion Medical Center (GHMC), 66 was constructed at Gunma University in 2010, followed by the Saga Heavy Ion Medical Accelerator in Tosu (SAGA HIMAT), 67 opened in 2013 under the SAGA HIMAT foundation. As of April 2016, the latest CIRT facility in Japan was established in Kanagawa (i-ROCK) 68 by the local Prefecture. Among the five CIRT facilities in Japan, scanning irradiation is employed at NIRS and i-ROCK.
Based on successful clinical trials at these facilities, CIRT was approved as an Advanced Medicine designation in 2003 by the Japanese government. Under this approval, CIRT was made available to the general public for privately paying patients, costing patients approximately 3.14 million JPY per treatment (irrespective to the number of fractions). In 2016, CIRT for unresectable sarcoma in bone and soft tissue became the first CIRT indication to be covered by the National Health Insurance system in Japan.
General clinical strategy at NIRS: Following the pioneering studies conducted at the Lawrence Berkeley Laboratory, 1 NIRS aimed to establish CIRT as a medical modality to treat cancer and to initiate phase I/II clinical trials on solid tumors that had progressed in various sites. 2 One of the primary endeavors of the clinical trials was to establish the optimal dose-fractionation schedule as well as irradiation technique for treatment.
These clinical trials employed a dose-escalation regime. In determining the starting dose level, the extent of local control as well as acute toxicity on surrounding organs at risk (OAR) was carefully monitored. As long as side effects noted in OARs was evaluated as tolerable, the prescribed dose was incremented stepwise until satisfactory tumor control was reached.
Another driving concern at NIRS was to investigate the efficacy hypofractionated CIRT. In general, tumor cells are regarded as deficient in repairing radiation injury as compared with normal tissue cells. In conventional radiotherapy, fractionated irradiations are, therefore, preferred to enlarge the differential response between tumor and normal tissues, i.e., to open the so-called therapeutic window. In contrast, particle therapy, including CIRT, offers superior dose conformity due to the finite range and the inverted depth-dose profile of ion beams. Thus, the dose to normal tissues can be kept below tolerable levels while delivering sufficient dose to the tumor, even in a shortened time course. If the tumor is still controlled and if no severe side effects occur, the reduction of overall treatment time is beneficial for patients from somatic as well as from the financial points of view.
Once the optimum dose is found in a given fractionation schedule, the subsequent clinical trials have evaluated further hypofractionation. For example, CIRT for non-small-cell lung cancer at NIRS was initially conducted with 18 fractions. Within clinical trials, the number of fractions was gradually reduced, and the treatment is now delivered in a single fraction using four treatment fields.
The main concern in hypofractionation is the increase in risk or severity of normal tissue toxicity. When starting a new hypofractionated phase I/II trial, a safer, lower starting dose was selected. This starting dose was determined by medical consideration, often supported by model-based analysis of the BED (Biological Equivalent Dose) or TCP (Tumor Control Probability).
The HIMAC typically runs from Monday to Saturday 24 h per day; however, only the daytime between Tuesday and Friday is exclusively available for therapeutic irradiations, while the remaining time is devoted to machine maintenance or research. Under these constraints, hypofractionated clinical trials at NIRS have been conducted using three or four fractions per week.
Treatment techniques at NIRS: CIRT at NIRS has initially been started with three treatment rooms in the HIMAC building. Two of these rooms are equipped either with fixed vertical or horizontal beam ports, while the third room has both, a vertical and a horizontal beam port. The beam ports are connected to the upper and lower ring of the double-decker synchrotron, respectively. Due to this accelerator design, therapeutic irradiation can be performed simultaneously in two rooms, while positioning a patient in the third room.
All beam ports in these original rooms are configured for broad-beam irradiation, 38 that is, they are equipped with a pair of wobbler magnets and a thin metal foil as a scatterer to enlarge the irradiation field laterally, and a ridge filter to spread out the Bragg peak (SOBP) in beam direction. Since the head and neck region was considered as one of the major targets, the RBE-depth profile of HSG (Human Salivary Grand) tumor cells at the 10% survival level was used to design ridge filters for absorbed depth-dose profiles with uniform RBE-weighted doses in the SOBP region. The available ridge filters at each port cover SOBP widths of 2-15 cm in 1-cm steps, and in therapeutic irradiations, the width of the ridge filter is selected to cover the maximum target thickness with the SOBP region. Finally, the irradiation field is tailored with a collimator and a range compensator manufactured for the radiation fields of the individual patient.
The broad beam is robust against setup errors for stationary targets. At NIRS, however, CIRT has been applied not only for stationary targets, such as tumors in the head and neck, central nervous system, eye, extremities, and prostate, but also for respiration-mobile targets in the lung, e.g. liver, pancreas, rectum, and uterus. To compensate for respiratory motion, the beam gating technique has been applied for the latter cases. 69 Respiratory motion is detected as the movement of an LED attached to the abdomen of the patient during treatment planning CT as well as during therapeutic irradiation. CT scan and therapeutic irradiation are then gated to the expiration phase where the motion of the target becomes minimal.
In 2011, in addition to the broad-beam ports, NIRS introduced the scanning irradiation technique in a newly built annex building, containing two additional therapeutic rooms. Both rooms are equipped with fixed vertical and horizontal scanning-beam ports.
The scanning system at NIRS uses the continuous 3D spot scanning technique. 70 The position of the pencil beam is controlled by a pair of scanning magnets, while the range in the patient is controlled by dynamically adjusting the energy extracted from the synchrotron accelerator.
The scanning technique is attractive due to its more conformal and flexible dose delivery to the target. However, due to the scanned beam, it is also less robust against setup errors or organ motion as compared to the passive beam delivery method. To apply the scanning technique also in case of moving tumors, substantial effort was made to develop a fast scanning system by accelerating the operation of scanning magnets and beam controlling devices. During irradiation, the beam is not switched off while shifting from one spot to the next and the transient dose between the spots is precisely considered in treatment planning.
After successful completion of a pilot study involving 11 patients with stationary disease in the prostate or head and neck region, the scanning technique is now applied also to mobile tumor sites, including tumors in the lung and liver. When treating moving targets with the scanning beam, the projected position of the target is monitored during irradiation by a real-time x-ray imaging using two perpendicular x ray imagers. 71 The beam is switched on only, if the target is at the planned position in the expiration phase. Moreover, the target is rescanned eight times to average-out hot or cold spots possibly appearing due to interference of beam and residual target motion. 72 With the passive beam method, the depth-dose distribution is determined by the shape of the ridge filter. Since the ridge filter is designed for a standard set of RBE-weighted SOBPs rather than for fields of individual patients, the depthdose distribution refers to a specific LET-depth profile and moreover does not depend on the prescribed dose. As both would change significantly for subsequent delivery of multiple fields, treatments are in principle conducted using only one port per day.
With the beam scanning technique and the more flexible MKM on the other hand, it is possible to optimize the depthdose distribution for the individual patient. While most scanning irradiations up to now have been conducted using one port per day, intensity-modulated ion-beam therapy (IMIT) with multiple fields has been recently introduced clinically for static targets.
Next to the two clinically operating scanning rooms, a third scanning room with a rotating gantry, employing superconducting magnets to bend the carbon beam, has been installed. 73 The use of the gantry is expected to be advantageous to further promote IMIT. After commissioning, clinical operation has begun in 2017.
2.C.2. Germany
In Germany, 440 patients were treated with CIRT between 1996 and 2008 at the Helmholtz Center for Heavy Ion Research (GSI) 74 and from 2009 on, treatments have been continued at the Heidelberg Ion Beam Therapy Center (HIT) 50 and since 2015 at the Marburg Ion Beam Therapy Center (MIT). Up to now, more than 2300 patients have been treated with CIRT at HIT using the solely the active raster scanning technique together with the LEM for RBE-weighted dose optimization. HIT and MIT are hospital based and provide carbon ions as well as protons either as a mono-modal treatment or in combination with a photon treatment.
At GSI, clinical operation focused on Phase I/II trials in skull base chordoma, 75 chondrosarcoma, 76 sacrococcygeal chordoma, 77 adenoid cystic carcinoma, 14 and prostate cancer. 78 CIRT at HIT continues in treating these indications within clinical trials and additionally established a number of clinical trial protocols for other tumor types. Since the beginning of clinical operation, a large number of singlecenter clinical trials have been established at HIT and most of them are in the phase of recruiting patients. [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] These trials may be separated into (a) trials testing a fully fractionated CIRT, (b) trials testing a photon treatment plus CIRT boost, and (c) trials testing CIRT with or without photon RT plus systemic therapy. A brief summary of these trials is given in the following.
Fully fractionated CIRT:
The most important question, whether the high-LET effect makes carbon ions superior over protons is addressed in two prospective randomized phase III trials in skull-base chordoma and chondrosarcoma. 79, 80 In these trials, patients are treated either solely with carbon ions or protons. Fractional doses are 3 Gy (RBE) for carbon ions and 2 Gy (RBE) for protons. Endpoint of the study is local progression-free survival, overall, progression-free and metastasis-free survival, as well as early and late toxicity. By comparing effectiveness and side effects in both study arms, the therapeutic advantage or disadvantage of CIRT can be assessed independently of the uncertainty involved in the RBE-weighted dose. All other clinical studies at HIT are presently designed as phase I, I/I, or II trials.
The response of sacrococcygeal chordoma is investigated comparing carbon ion vs. proton treatments. 90 In contrast to the earlier studies, ion therapy was applied fully fractionated and the fractional dose was raised to 4 Gy (RBE) per fraction. Endpoints of the study are toxicity, local progressionfree and overall survival, and quality of life.
For recurrent glioma after RT, a dose-escalation study is performed to find an adequate dose prescription for CIRT and the resulting therapy schedule is then compared with a standard fractionated stereotactic photon trestment. 81 Endpoints of this trial are progression-free and overall survival, toxicity, and safety.
In the previous study at GSI, 78 prostate cancer has been treated with photons plus a CIRT boost. In contrast, fully fractionated carbon ion and proton treatments are compared at the present trial at HIT using the same fractional dose of 3.3 Gy (RBE) for both ion types. 92 Endpoint of the trial is toxicity, PSA-progression-free and overall survival, and quality of life. An additional trial with hypofractionated carbon ion and proton treatments was initiated.
In a one-armed trial, the response of recurrent rectal carcinoma after RT is studied. After an initial dose-escalation phase, CIRT is performed with the maximal tolerable dose. 87 Endpoints are progression-free and overall survival, toxicity, and safety. In another one-armed trial, the feasibility of high-dose treatments given in only four fractions is tested in hepatocellular carcinoma after an initial doseescalation study. 88 Endpoint of the study is toxicity, imaging response, and progression-free survival. As in the case of rectal carcinoma, special attention is paid to compensation of organ motion. This was mostly realized by an abdominal compression plate and in a few cases by respiratory-gated treatments.
Photon treatment plus CIRT boost: Due to the relatively large uncertainty of the RBE-weighted dose, CIRT is often applied as a boost additional to a photon treatment to avoid exceeding the tolerance limits of the tumorsurrounding normal tissue. In atypical meningioma, a postoperative photon treatment is combined with a 6 9 3 Gy (RBE) carbon ion boost to study the endpoint progression-free survival. 83 In inoperable malignant salivary gland tumors, feasibility of a standard IMRT photon treatment combined with a 8 9 3 Gy (RBE) carbon ion boost is tested. 84 Endpoint of this trial is mucositis, late toxicity, local control, and diseasefree survival. CIRT with or without photon RT plus with systemic therapy: While CIRT has the potential to increase local tumor control, systemic therapy such as chemo-or immunetherapy is still required to minimize the impact of potential or actual metastatic diseases. For adenoid cystic carcinoma, a standard IMRT photon treatment plus a 6 9 3 Gy (RBE) carbon ion boost is combined with weekly doses of Cetuximab. 85 Endpoint of this study is toxicity, local and distant control, as well as disease-free and overall survival.
In primary glioblastoma, a standard treatment with photons and temozolomide is combined either with 6 9 3 Gy (RBE) carbon ions or 5 9 2 Gy (RBE) protons and is compared with respect to overall and progression-free survival, toxicity, and safety. 82 For locally advanced, nonmetastatic squamous cell carcinoma, 50 Gy photon IMRT plus 8 9 3 Gy (RBE) carbon ions are combined with TPF and Cetuximab treatments. 86 Endpoint of this trial is local control, disease-free survival, progression-free survival, and overall survival as well as toxicity.
In a pilot trial, tumors of the superior sulcus are treated with standard chemotherapy plus 13 9 3 Gy (RBE) carbon ions. 91 Endpoint of this study is toxicity, histological, metabolic, and morphologic tumor regression.
Finally, for high-grade osteosarcoma, standard chemotherapy is combined with a proton treatment and a dose-escalated carbon ion boost. 89 Endpoint of this trial is toxicity, tumor response in FDG-PET, disease-free survival, and overall survival.
2.C.3. Italy
The National Center for Oncological Hadrontherapy CIRT is delivered with multiple fields per day that are optimized simultaneously with an IMPT approach. All planning and delivery characteristics are basically identical to those employed at HIT; nevertheless, when clinical operation started at CNAO, most of the available clinical data originated from Japan, where more patients with a larger variety of tumors had been treated and data for longer follow-up was available. At CNAO treatment, protocols were designed to reproduce clinical results of NIRS. The fractionation schedule was reproduced, delivering four fractions per week, and fraction size was derived from preclinical RBE-weighted dose comparisons. From 2011 to 2013, treatments were performed within prospective trials that were requested by the Italian Ministry of Health notifying body to obtain the CE label. In 2013, the CE label was achieved for a restricted number of indications, and since September 2016, it was extended to all tumors potentially treatable with hadron therapy. In the following section, we briefly describe the applied treatment protocols employing the notation Gy (RBE_NIRS) or Gy (RBE_LEM) to specify, which model was used for RBE calculation.
Inoperable, residual (including microscopically positive R1 margins), or recurrent adenoid cystic carcinoma have been treated with carbon ions. Doses employed at NIRS were either 16 9 3.6 Gy (RBE_NIRS) or 16 9 4.0 Gy (RBE_ NIRS). At CNAO, doses of 16 9 4.3 Gy (RBE_LEM) over 4 weeks have been used. The nominally different dose of 4.3 Gy (RBE_LEM) was considered as the best approximation to the NIRS treatment. Until September 2016, 159 patients have been treated. Final results have not been published yet. Dose constraints were derived from carbon ion-specific toxicity data from NIRS. For example, dose constraints for optic nerve were set at D max < 40 Gy (RBE_ LEM) and D 20% < 28 Gy (RBE_LEM). 93 In the dose range of 1-5 Gy (RBE_NIRS) and applying these dose constraints at this nominal dose value is a conservative approach and entails a lower risk of toxicity.
The same schedule of 16 9 4.3 Gy (RBE_LEM) over 4 weeks has been used to treat 16 patients with malignant melanoma of the head and neck mucosae and 22 patients with malignant tumors of the lachrymal glands.
A lower dose of 16 9 4.1 Gy (RBE_LEM) over 4 weeks has been employed to treat selected patients with recurrent pleomorphic adenoma of the parotid that were no longer candidate to curative surgery. In total, 32 patients have been treated so far.
Skull base chordoma with macroscopic residual disease were treated with 16 9 4.4 Gy (RBE_LEM) over 4 weeks. This schedule resembles a dose between 3.9 and 4.0 Gy (RBE_NIRS). At NIRS, the prescription dose was slightly lower [3.8 Gy (RBE_NIRS)]; however, in CNAO, the favorable subset of skull base chordoma with minimal or no residual disease was treated with protons. Until September 2016, 41 patients have been treated.
Nonchordoma head and neck, bone, and soft-tissue sarcoma have been treated at doses between 16 9 4.4 and 16 9 4.8 (RBE_LEM) over 4 weeks. The highest dose was used in most cases to reproduce results of NIRS [16 9 4.4 Gy (RBE_NIRS)], but the lower doses were occasionally employed in patients having a high risk of severe toxicity because of extensive infiltration of critical structures. Until September 2016, 79 patients have been treated.
The constraint for brain stem was the same as the one employed in clinical practice at NIRS [D max < 40 Gy (RBE_LEM)], and it was conservatively employed for the nominal dose value. This was rather often a limiting factor in achieving good target coverage. In selected cases of chordoma, in which the GTV abutted the brainstem, the German fractionation schedule of 22 9 3 Gy (RBE_LEM) with five fractions per week was employed using the dose constraint D max < 57 Gy(RBE_LEM).
Inoperable or residual sarcoma in the chest, abdomen, and pelvis was treated with carbon ion doses between 16 9 4.4 and 16 9 4.8 (RBE_LEM) over 4 weeks. Until September 2016, 173 patients have been treated.
Seventeen high-risk prostate cancer patients were treated with concomitant endocrine therapy (LH-RH analogous) using a schedule of 16 9 4.15 Gy (RBE_LEM) over 4 weeks. Dose constraints for the rectum were derived from the NIRS experience and were D max < 61 Gy (RBE_LEM) and D 5% < 56 Gy (RBE_LEM) for the nominal dose values.
Carbon ions have also been used for re-irradiation of tumors, which are traditionally considered as radio-resistant, such as melanoma, sarcoma, or salivary gland tumors, or in cases where the recurrence was inside the previous irradiation field, and therefore, the selection of radio-resistant clones could be hypothesized. In addition, re-irradiations were performed in cases where the recurrence was very close to critical organs (e.g., the optic chiasm) that could be better spared by carbon ions.
One hundred twenty-eight recurrences of head and neck tumors, 13 recurrences of spinal chordoma, and 8 recurrences of rectal cancer have been treated up to September 2016. Prescribed doses were depended on the previous therapies and were selected individually. The most frequently applied schedules were 12 9 4.8 Gy (RBE_LEM) in 3 weeks, mimicking the NIRS fractionation schedule or 20 9 3.0 Gy (RBE_LEM) in 4 weeks reproducing the HIT schedule.
Since September 2014, treatments of moving targets are performed at CNAO. The treatment procedure includes the use of abdominal compression devices and a 4D-CT scan, contouring and planning in end expirative breathing phase, robustness check in the adjacent 30% expiration and 30% inspiration phases using iterative manual optimization, gated delivery, and 5-fold rescanning of each energy layer. The commercial Anzai TM system is used to generate a surrogate breathing signal during 4D-CT and treatment delivery. Infrared markers and stereotactic cameras are additionally used to independently check the respiratory phase. So far, 28 patients have been treated. Eleven of them had inoperable pancreatic adenocarcinoma and were treated at 12 9 4.8 Gy (RBE_ LEM) in 3 weeks and 7 had hepatocellular carcinoma and were treated at 12 9 4.6 -12 9 5.0 Gy (RBE_LEM). In the latter case, the dose was selected depending on proximity to bowel and hepatic hilum.
The clinical results of CNAO have not yet been published. The main reason for this is the still rather short follow-up; however, analysis of outcome and toxicity in comparison with NIRS data are ongoing. The potential impact of selection bias in these analyses is a major issue, and attempts to retrospectively match cases for known factors are made. As a very preliminary result, skin and mucosal toxicity have been less severe at CNAO for patients with comparable diseases and, as a hypothesis, this may be attributed to the higher degree of conformity when using scanned beams. On the other side, local control has been somewhat lower at CNAO; however, the excess of local recurrences has been observed in close proximity to organs at risk. With this respect, the Japanese approach has traditionally given priority to target coverage, accepting also exceeding of the supposed tolerance doses of OARs, while CNAO accepted some significant under dosages of target volume instead, to fully respect the dose constraints for the spinal cord, the brainstem, and the optic chiasm. If patients with comparable target coverage at CNAO and NIRS are analyzed, local control is quite similar. These results will be published in detail in separate papers.
DISCUSSION
CIRT has evolved to a mature technology and has been applied in more than 20,000 patients up to now. 74 Nevertheless there are a number of open radiobiological issues, which have to be addressed by further investigations and standardization.
3.A. Limitations of RBE models
For CIRT, the RBE has shown to be a practical concept to consider the strongly varying biological effectiveness within the treatment field. It has to be emphasized that RBE in radiobiology is a well-defined and measurable quantity and in the frame of radiobiological experiments, it fulfills what its name promises: 3 Gy (RBE) of carbon ions really produce the same effect as 3 Gy of photons, if the RBE refers to the selected endpoint. In the clinical setting, however, the RBE becomes a much worse defined concept. For a series of reasons, it is not true in any clinically meaningful way that 3 Gy (RBE) of carbon ions produces the same effect of 3 Gy of photons:
First, in the clinical setting, we are always interested in multiple clinical endpoints. As a minimum, we care about acute toxicity, late toxicity, and local control (defined as lack of local recurrence in the medium and long term). If a curative (as opposed to adjuvant) irradiation is performed, we also care about tumor response (e.g., tumor shrinkage or change of functional properties, such as FDG or methionine uptake, in the short term). All these endpoint have a different dependency on LET and fractionation and therefore also a different RBE. If we focus on short-term tumor response and if we generate a plan that is isoeffective to a uniform dose of photons for this endpoint, this plan will not be isoeffective to the same photon plan for the other relevant endpoints.
Second, intrinsic radiobiological properties of tumors and normal tissues are heterogeneously distributed across a patient population as well as within an individual patient. Especially in tumors, this variability may be significant, e.g., due to the presence and spatial distribution of hypoxia or radioresistant tumor cells. This is a general problem, which is not limited to CIRT. Also in photons RT, it is very difficult to fit clinical local control data with TCP models based on a single value of radiobiological parameters, and more realistic attempts have to include a probability distribution of those parameters (e.g., clonogenic density and value of a). 94, 95 In CIRT, these difficulties are only enhanced as less data and clinical experience are available. Third, the effect of fractionation plays a major role, which is not accounted for by any existing model. It is well known that the tumor micro-milieu (not to mention surrounding healthy tissues) respond adaptively during the RT course. For example, at fraction number 6 delivered at day number 8, the amount of hypoxic and well oxygenated tumor cells, the distribution in the cell cycle, the amount of quiescent and proliferating tumor cells, the local concentration of growth factors, the amount of intracellular signal activation, to list only a few, will be definitely different from what they were at fraction number 1. The same dose of photons will produce a different effect at the first and at the sixth fraction. In principle, the same holds for carbon ions; however, quantitatively, there will be a difference between both modalities. Therefore, the clinical RBE at the first fraction will differ from that at the sixth fraction. If fractionated in vitro or in vivo experiments are performed, usually, the effect over all fractions is observed and attributed uniformly to each fraction. This must be considered as a substantial approximation. Unfortunately, the majority of RBE experiments performed in vivo and in vitro are based on single fractions and even those performed with fractionated irradiations cannot discriminate biological changes during treatment, as the endpoint can only be detected after giving the total dose. The relationship between the total dose needed to produce a certain degree of erythema in mice and number of fractions is one of the few cases, where the effect of each fraction can be observed.
A mouse model has been used to investigate the in vivo skin response to CIRT with different LET spectra and fractionations. In this experiment, passively generated SOBP was delivered perpendicularly to the skin's surface leading to an exposure with a uniform beam quality at each depth of the SOBP. As can be seen in Fig. 2 , the adaptive response of the skin cannot be neglected and the dependence of the total dose on the number of fractions shows a nonlinear relationship which is qualitatively different for different depths in the SOBP, that is, for different LET spectra. This behavior can hardly be explained with a simple LQ approach. Therefore, it can be concluded that transferring RBE values derived from single to fractionated treatments, in which the same dose per fraction is delivered multiple times, introduces a significant error. Even data obtained from fractionated experiments should be extrapolated to different fractionation schedules only with the utmost care.
In conclusion, we could prescribe 3 Gy (RBE) of CIRT to a patient in Europe using the LEM and prescribe the same RBE-weighted dose to a similar patient in Japan with the phenomenological mixed-beam model. The RBE-weighted dose volume histograms (DVH) may look identical, voxel by voxel, the RBE weighted dose may have minimal variability (i.e., well below the typically considered AE 5% threshold), but the two treatments will be significantly different in terms of local control probability and risk of toxicity. Neither of the two will be isoeffective to 3 Gy of photons for any of the relevant clinical endpoints.
3.B. Comparing treatment results of different institutions
Comparing treatments and treatment results of CIRT performed at facilities employing different RBE model is a challenging task. On one hand, it is not possible to simply compare absorbed doses, since the effect depends also on the underlying beam quality (i.e., the LET/y spectra); on the other hand, the total absorbed dose is the only model-independent dose quantity we have.
Two different approaches have been used to tackle this issue: the first is to start with treatment plans that were originally optimized with one RBE model and to recalculate the RBE-weighted dose distribution with a different RBE model on basis of the fluence pattern of primary and secondary particles connected to the absorbed dose distribution. 96, 97 With this approach, a set of pancreatic cancer patients treated at NIRS was studied with mixed-beam model on the one and LEM on the other hand. Results of these treatments are reported in the literature. 20 The prescribed dose at NIRS after a dose-escalation phase was 55.2 Gy (RBE) given in 12 fractions. If these treatment plans were converted to LEMbased RBE-weighted dose distributions, they were not homogeneous within the target, and the average RBE-weighted doses were different from those reported for the actually performed treatment.
Unfortunately, it is not easy to access all the underlying physical quantities to recalculate the RBE-weighted doses. The clinical treatment planning system (TPS) only reports some of the required input data and the approach used so far relied on MC simulations with FLUKA, which includes a model of the beam line, patient-specific hardware, and the patient anatomy. 97, 98 Initial results of a cooperative project between NIRS, Gunma, and CNAO have been published, and further studies are ongoing, aiming at recalculating a large number of plans for different indications. To support these activities, it would be desirable to develop an international DICOM-based standard to additionally report voxelby-voxel LET/y distributions for the primary and secondary particles.
The described approach addresses the question, how the RBE-weighted dose distribution would look like, if the same fluence pattern of particles would be delivered to the patient, but if a different RBE model would be used. There is a clinically meaningful, however, not identical question: Which dose should be prescribed when using a different RBE model to achieve results similar to those reported by another facility?
This question has been addressed in a second approach, which compares the underlying absorbed dose distributions rather than the prescribed RBE-weighted doses. 99 The idea behind this approach is that identical absorbed dose distributions produced by identical beam configurations to identical target volumes will lead to a comparable biological effect, because their voxel-by-voxel LET/y distribution will be very similar. As one may expect, approaches 1 and 2 produce very similar results. 3.C. Summary of current evidence CIRT has been used clinically for more than 20 years, and its safety and efficacy has been established for several indications. 2 Results of CIRT and protons/photons series are extremely difficult to compare as a significant proportion of patients treated with CIRT had bulky, nonresected diseases and would not have been candidates to radical low LET therapy.
High total doses have been prescribed in CIRT with moderately or extremely hypofractionated schedules within doseescalation trials. With the exception of IMP, all the facilities have used a strategy to optimize and report dose based on a locally varying RBE that was calculated with a mathematical model and was multiplied voxel-by-voxel with the absorbed dose. Japanese facilities have employed the mixed-beam model (and more recently also the MKM model) and have established prescription doses and OARs dose constraints. Historically, all Japanese centers have been using the mixed model beam or the MKM. Treatments have been delivered in a very short time (<1 min) using a single beam per day and 4-5 fractions per week. European facilities, however, have all used the LEM model in combination with active scanning to deliver multiple fields per day and 4-7 fractions per week. Due to the scanning technique, the delivery time was in the order of several minutes.
Nominal prescription doses for moderately hypofractionated schedules have been between 3 and 4.8 Gy (RBE) in Japan, and it has typically been 3 Gy (RBE) in Germany. Extreme hypofractionated treatments have been performed in Japan for liver and lung cancer at doses per fraction of more than 20 Gy (RBE). 100, 101 Results have been already obtained in a small number of facilities. For the future, there is the need to confirm reproducibility of results reported by single facilities and to run multicentric trials. It has to be stressed that delivering CIRT in Europe with prescription doses and dose constraints taken at the nominal values from Japanese experience is not correct. For moderately hypofractionated treatments consisting of 12-16 fractions with dose per fraction between 3.6 and 4.8 Gy (RBE), this is supposed to result in a lower tumor control probability. 96, 97, 99 The CNAO approach for converting prescription doses is currently being used, but it still needs definitive validation. If dose constraints are taken at nominal value from the Japanese experience, no excess of toxicity is expected; however, suboptimal target coverage may result from the attempt to respect overcautious constraints. For severely hypofractionated schedules, the Japanese approach disregarded the dependence of RBE on dose per fraction. However, the LEM predicts an RBE very close to one for absorbed doses in the range 20-40 Gy. Therefore, if the same nominal doses would be prescribed in Europe with LEM for Lung and liver treatments, a major increase in toxicity would be expected. Facilities trying to reproduce results obtained with different RBE models are responsible for evaluating these sources of uncertainties and considering these in the treatment.
In multicentric prospective clinical trials, participating facilities should agree on the strategy for comparison of RBE weighted doses, if different RBE models are used at different facilities. This should include the employment of different nominal prescription doses and dose constraints for both RBE models. Within prospective trials, it should be achieved that facilities do not only report RBE weighted doses based on the used model but also the RBE weighted doses as they result from application of the alternative RBE models assuming the delivery of the same particle fluence.
3.D. Future challenges
Despite extensive clinical application, CIRT is still in the process of moving from an experimental tool to a clinically available option. There is a large agreement in the CIRT community that reproducing mono-institutional results and establishing agreed sets of dose constraints for OARs that account for the different RBE models is of top priority. Moreover, there is request by the broader oncological community to test at least some of the indications in prospective randomized trial against other kinds of RT. It is also clear, however, that several new developments and lines of research should be pursued. It is beyond the scope of this article to summarize all foreseen developments of CIRT, but it is important to mention those that may involve issues regarding RBE uncertainties similar to or even more delicate than those discussed above. One issue that is currently investigated is the possibility to describe quantitatively at least some of the parameters that affect RBE, most importantly tumor hypoxia. [102] [103] [104] [105] [106] [107] Measuring the voxel-by-voxel degree of hypoxia and using these data to modify the voxel-by-voxel RBE could be interesting for both, to describe what is being delivered in case oxygenation without considering oxygenation in the RBEweighted dose optimization, and maybe also use this information within the optimization process. In photon RT, the only suggested modification of the treatment plan is to escalate the dose either uniformly or to increase the dose selectively in the hypoxic regions using "dose-painting." In contrast, CIRT offers the ability to use dose-as well as LET-painting. To deliver dose-or LET-painting in a meaningful way, the day by day variation of hypoxia during RT has to be considered. It should be clear that the uncertainty in estimating the degree of hypoxia would add to the RBE uncertainty in an unpredictable way.
A second possible future approach is to account for RBE uncertainties and to aim for robust biological optimization of the treatment plan. 108 This approach would also involve some degree of LET painting but may sacrifice RBE weighted dose homogeneity for the nominal plan visualized by the TPS. Once again, this approach may have interesting clinical applications but would make interpretation of results even more difficult.
In the future, other ion species may become available for clinical use. Helium ions are currently being investigated because they compare favorably with protons in terms of lateral penumbra and spot size. 49, 109 However, the independent role of the LET is assumed to be comparable to that of protons rather than carbon ions. However, oxygen ions are considered as a promising candidate to treat bulky resistant tumors due to the increased LET over the whole target volume as compared with carbon ions. Also mixed ion beam treatments have been suggested, which would result in an LET-painting approach. 110 As a general remark, the current trend is toward an optimization of CIRT that accounts for specific patient-, tissue-, and tumor-related factors. This is a development toward an individualized therapy that must, of course, be validated with clinical data. This likely future development requires an even more stringent strategy in reporting the delivered treatment in terms of selected physical quantities, on which agreement should be achieved.
CONCLUSION
CIRT prescription, optimization, recording, and reporting are performed with a practical approach based on RBEweighted dose. RBE-weighted dose is calculated by multiplying voxel-by-voxel the absorbed dose and a model-based RBE. This RBE is assumed constant over the whole fractionation course. Clinical validation typically relies on a single observable clinical endpoint (e.g., tumor control or loss of function in OARs). Several different models are used to calculate RBE and clinical data cannot determine uniquely, which model is more accurate. To retrospectively compare results of different facilities, nominal reported RBE doses are not sufficient. Relying only on these nominal reported RBE weighted doses is an incorrect and potentially dangerous way when trying to reproduce results of other facilities. Accordingly, in prospective multicentric trials, prescription doses and dose constraints should not be set at nominal identical values among facilities using different RBE models, rather it should be agreed on adapted values minimizing the difference of the effectiveness of the delivered treatments in both facilities. Comparison of treatments performed with different RBE models has been done in the framework of international cooperations between facilities and the main strategies have already been identified. There is urgent need to standardize, how comparison should be performed and which physical parameter should be reported and which format should be used.
